Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al.
Merel J l'AmiCharlotte L M KrieckaertMichael T NurmohamedRonald F van VollenhovenTheo RispensMaarten BoersGerrit Jan WolbinkPublished in: Annals of the rheumatic diseases (2017)